Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States

Dec 19, 2006, 00:00 ET from Trillium Therapeutics Inc.

    TORONTO, Dec. 19 /PRNewswire/ - Trillium Therapeutics Inc. (Trillium)
 today announced that its gastrointestinal product, TTI-1612, has been
 designated an Orphan Drug by the European Medicines Agency (EMEA), and the
 U.S. Food and Drug Administration (FDA), for the prevention of necrotizing
 enterocolitis (NEC).
     "Orphan drug status provides TTI-1612 with up to seven and ten years of
 market exclusivity in the US and Europe respectively, which significantly
 enhances its commercial potential", said CEO Dr. Niclas Stiernholm. "This
 may also generate opportunities for additional funding, as well as expert
 advice and assistance with regulatory issues and trial design."
     TTI-1612 is a small, orally-available recombinant protein that has
 powerful cytoprotective and anti-inflammatory effects. It has shown
 remarkable efficacy in preclinical animal models of NEC and intestinal
 ischemia/reperfusion injury, and may have additional utility in the
 treatment of other intestinal disorders, such as short bowel syndrome,
 inflammatory bowel disease and chemotherapy-induced mucositis.
     "NEC is now the most common surgical emergency procedure in the
 neonatal intensive care unit. Despite significant advances in neonatal
 care, the morbidity and mortality rates of this disease have not improved
 over the past 30 years. Approximately 30% of afflicted neonates die of
 NEC-related complications", added Dr. Craig Binnie, Trillium's Director,
 Drug Development. "Trillium's TTI-1612 drug candidate represents a
 promising new tool in the quest to prevent this devastating condition."
     About Trillium:
     Trillium Therapeutics Inc. is a private biopharmaceutical company
 specializing in innovative therapies that restore balance to the immune
 system in conditions associated with aberrant and harmful immune responses.
 These include autoimmune and inflammatory disorders, graft rejection,
 cancer and chronic viral diseases. In addition to its gastrointestinal
 inflammatory disease program, TTI currently has two scientific platforms
 encompassing five proprietary product opportunities at various stages of
 preclinical development. The first platform involves the recently
 identified CD200 immunoregulatory protein and its receptor. These represent
 novel targets for the treatment of a variety of autoimmune diseases and
 cancer. The second platform is focused on the activating receptor, FcRIIa,
 implicated in several autoimmune diseases, including rheumatoid arthritis
 and lupus. The company has a broad network of external academic and
 industry relationships, including some with major US and European
 biotechnology and pharmaceutical companies.

SOURCE Trillium Therapeutics Inc.